These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 35022014)

  • 21. Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial.
    Maraone A; Trebbastoni A; Di Vita A; D'Antonio F; De Lena C; Pasquini M
    JMIR Res Protoc; 2023 May; 12():e39223. PubMed ID: 37166948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study.
    Stryjer R; Budnik D; Ebert T; Green T; Polak L; Weizman S; Spivak B
    Clin Neuropharmacol; 2014; 37(3):79-81. PubMed ID: 24824662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.
    Pediatric OCD Treatment Study (POTS) Team
    JAMA; 2004 Oct; 292(16):1969-76. PubMed ID: 15507582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D; de Geus F; van Megen HJ; Westenberg HG
    J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
    Tzavellas E; Karaiskos D; Ilias I; Liappas I; Paparrigopoulos T
    Psychiatriki; 2014; 25(3):179-84. PubMed ID: 25367661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder.
    Stewart SE; Jenike EA; Hezel DM; Stack DE; Dodman NH; Shuster L; Jenike MA
    J Clin Psychopharmacol; 2010 Feb; 30(1):34-9. PubMed ID: 20075645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination Therapy of Serotonin Reuptake Inhibitors and Memantine for Obsessive- Compulsive Disorder: A Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
    Kishi T; Matsuda Y; Iwata N
    J Alzheimers Dis; 2018; 64(1):43-48. PubMed ID: 29865079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.
    Shalbafan M; Malekpour F; Tadayon Najafabadi B; Ghamari K; Dastgheib SA; Mowla A; Shirazi E; Eftekhar Ardebili M; Ghazizadeh-Hashemi M; Akhondzadeh S
    J Psychopharmacol; 2019 Nov; 33(11):1407-1414. PubMed ID: 31575326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A study of cognitive function in treatment-refractory obsessive-compulsive disorder treated with capsulotomy.
    Gong F; Li P; Li B; Zhang S; Zhang X; Yang S; Liu H; Wang W
    J Neurosurg; 2018 Feb; 128(2):583-595. PubMed ID: 28338440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
    Esalatmanesh S; Abrishami Z; Zeinoddini A; Rahiminejad F; Sadeghi M; Najarzadegan MR; Shalbafan MR; Akhondzadeh S
    Psychiatry Clin Neurosci; 2016 Nov; 70(11):517-526. PubMed ID: 27488081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control.
    Naderi S; Faghih H; Aqamolaei A; Mortazavi SH; Mortezaei A; Sahebolzamani E; Rezaei F; Akhondzadeh S
    Psychiatry Clin Neurosci; 2019 Apr; 73(4):169-174. PubMed ID: 30488617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.
    Berlin HA; Koran LM; Jenike MA; Shapira NA; Chaplin W; Pallanti S; Hollander E
    J Clin Psychiatry; 2011 May; 72(5):716-21. PubMed ID: 20816027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study.
    Emamzadehfard S; Kamaloo A; Paydary K; Ahmadipour A; Zeinoddini A; Ghaleiha A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    Psychiatry Clin Neurosci; 2016 Aug; 70(8):332-41. PubMed ID: 27106362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 2-year study of sertraline in the treatment of obsessive-compulsive disorder.
    Rasmussen S; Hackett E; DuBoff E; Greist J; Halaris A; Koran LM; Liebowitz M; Lydiard RB; McElroy S; Mendels J; O'Connor K
    Int Clin Psychopharmacol; 1997 Nov; 12(6):309-16. PubMed ID: 9547132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Bullock KD; Franz B; Gamel N; Elliott M
    J Clin Psychiatry; 2005 Mar; 66(3):353-9. PubMed ID: 15766302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.
    Ninan PT; Koran LM; Kiev A; Davidson JR; Rasmussen SA; Zajecka JM; Robinson DG; Crits-Christoph P; Mandel FS; Austin C
    J Clin Psychiatry; 2006 Jan; 67(1):15-22. PubMed ID: 16426083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.